Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia

A neurodegenerative and composition technology, applied in the field of schizophrenia, can solve the problems of unsatisfactory treatment and/or prevention of neurodegenerative disorder schizophrenia, and achieve the effect of low price

Inactive Publication Date: 2008-08-06
UNIV DE BARCELONA +1
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Despite all the research efforts invested in the past, the treatment and / or prevention of neurodegenerative disorders such as Alzheimer's disease or schizophrenia is still far from satisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
  • Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
  • Pharmaceutical compositions comprising a tungsten salt (VI) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Effect of Tungstate on Ser-9 Phosphorylation of GSK3-β in Neuroblastoma Cell Line SH-SY5

[0034] To investigate whether tungstate affects neuronal cells, the effect of sodium tungstate dihydrate on GSK3-β in the neuroblastoma cell line sH-SY5Y (ref: 94030304 of the European Collection of Cell Cultures, Salysbury, Whitshire, Great Britain) was analyzed Effects of Inhibition of Ser-9 Phosphorylation. Human neuroblastoma SH-SY5Y cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBs; Invitrogen-Gibco), 2 mM glutamine, and 50 μg / ml gentamicin. ; Invitrogen-Gibco, Carlsbad, CA). The day before the experiment, cells were plated in multi-well plates with NeuroBasal (NB) serum-free medium (Invitrogen-Gibco). Sodium tungstate dihydrate was dissolved in double distilled water and added to the incubation medium at a final concentration of 0.1, 1 or 5 mM, and the cells were incubated for 5 or 10 minutes. Control cell...

Embodiment 2

[0037] Example 2: Effect of sodium tungstate on tau phosphorylation in vivo

[0038] To study the effect of tungstate on tau phosphorylation in vivo, the phosphorylation degree of this protein and the phosphorylation degree of GSK3-β at Ser-9 in untreated and tungstate-treated healthy Wistar rat brains were first analyzed. Male Wistar rats (IFFA CREDO, L'Arbresse, France) weighing 220-240 g were housed one cage per animal on a 12:12-hour light-dark cycle under controlled temperature and humidity. In each group in the presence or absence of tungstate, no significant changes in tau or GSK3 phosphorylation were observed (Fig. 2A). These results are consistent with previous data showing that tungstate was inactive when tested in healthy animals.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for the treatment of neurodegenerative disorders, comprising an effective amount of a tungsten (VI) compound, preferably tungstate, and more preferably sodium tungstate (Na2WO4). The pharmaceutical composition of the present invention can be used for the preventive and / or therapeutic treatment of neurodegenerative disorders in mammals (including humans), and especially in the preventive and / or therapeutic treatment of Alzheimer's disease and schizophrenia. The effect of sodium tungstate dihydrate on tau phosphorylation was evaluated in rat models of insulin resistance and type 1 diabetes. Therapeutic treatment of Tau-associated diseases from the present invention includes several advantages: GSK3 inhibition; specificity, since it reduces abnormal hyperphosphorylation of tau caused by nerve-specific proteins; efficacy; lack of toxicity; and low price.

Description

technical field [0001] The present invention relates to the use of pharmaceutical compositions comprising tungsten(VI) compounds for the treatment of neurodegenerative disorders, in particular Alzheimer's disease and other microtubule-associated diseases (i.e. involving deposition of abnormal microtubule-associated protein isoforms in the brain neurodegenerative disorders), and schizophrenia. Background technique [0002] Neurodegenerative disorders can be defined as chronic and progressive disorders of the nervous system affecting neurological and behavioral function, beginning with specific biochemical changes that culminate in distinct histopathological and clinical syndromes. Among these disorders are Alzheimer's disease, Huntington's disease and Parkinson's disease. [0003] Alzheimer's disease, the most common form of dementia in older adults, involves the parts of the brain that control thought, memory and language. It is characterized by two main pathological marke...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/24A61P25/18A61P25/28
CPCA61K33/24A61P25/00A61P25/14A61P25/16A61P25/18A61P25/28
Inventor J·J·奎诺瓦特希瑞拉J·埃维拉德格拉多J·道明奎兹雷耶斯R·格密斯德芭芭拉A·格默兹拉默斯D·扎夫拉洛佩兹H·克罗米诺拉欧卡纳
Owner UNIV DE BARCELONA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com